Neupogen
information and resources from the National Cancer Institute
Neupogen
(Other name for: filgrastim)Neupogen
(Other name for: filgrastim)
Filgrastim Amgen, Inc Feb 20 1991
Filgrastim
NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation hemotherapy treatment of adults with AML.
Amgen, Inc Apr 02 1998
Filgrastim
NEUPOGEN is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.
Amgen, Inc Apr 02 1998
Filgrastim
NEUPOGEN is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation.
Amgen, Inc Apr 02 1998
|
|
|
|
news articles
Long-Term Study Shows Safety of Neupogen® Support in AML ... Mar 17, 2006
Cancer Consultants (press release), Researchers affiliated with The International Acute Myeloid Leukemia Study have reported that the use of Neupogen (filgrastim) to support intensive induction ...
Long-Term Study Shows Safety of Neupogen® in AML Treatment Mar 17, 2006
Cancer Consultants (press release), According to a recent article published in the journal Leukemia, the growth factor Neupogen® (filgrastim) is safe and effective when used in the treatment ...
Man Convicted for Role in South Florida Drug Adulteration Ring, US ... Mar 28, 2006
Lawfuel (press release), Prescription drugs sold by the crime ring included Neupogen, used for cancer and HIV patients; Gammagard (Gamimune, Iveegam and Panglobulin), used for HIV ...
Heart-attack patients not helped by Amgen drug Mar 1, 2006
Ventura County Star (subscription), The study, published in the Journal of the American Medical Association today, gave patients a daily dose of Neupogen, a drug produced by Amgen Inc. ...
Demand to expand Mar 28, 2006
TMCnet Manufacturing also is being expanded at a cost of $1 billion in Puerto Rico to boost capacity for drugs produced there -- Epogen, Aranesp, Neupogen and Neulasta ...
Guilty verdict in AIDS drug scam Mar 28, 2006
Miami Herald, Medications such as Epogen, a drug for kidney dialysis and cancer patients, and Neupogen, used for cancer and HIV patients, were diluted, relabeled and sold to ...
A sister's gift of love Mar 27, 2006
Cheboygan Daily Tribune (subscription), Anna received shots of the drug neupogen for four days to stimulate stem cell production and “push� the stem cells out of the bone marrow and into her ...
Amgen Drug Fails to Aid Heart Recovery in Test Mar 1, 2006
Los Angeles Times, Researchers in Germany used Thousand Oaks-based Amgen's Neupogen in a technique that in previous studies had improved the cardiac function of heart attack ...
RQ-PCR Positivity Predicts Relapse of Mantle Cell Lymphoma after ... Mar 9, 2006
Cancer Consultants (press release), Stem cells were mobilized with chemotherapy and Neupogen® and all but one patent had stem cell products that were positive by PCR for minimal residual disease ...
Where Will You Be Tomorrow? Mar 13, 2006
Motley Fool Amgen (Nasdaq: AMGN) may have won you over with the success of Epogen and Neupogen, but it's the probability of us living longer -- and healthier -- lives that ...
Mobilizing bone marrow stem cells doesn't repair heart, study ... Feb 28, 2006
Kentucky.com, The patients were randomly assigned to receive injections of a placebo or Neupogen, a bone marrow-stimulating drug widely used to spur replacement of white ...
A Lisa Pierot tribute: Part 6: 2004-2005 Mar 3, 2006
Palm Beach Post, The two weeks following my first chemo were hell. My white counts plummeted, and so they gave me multiple shots of Neupogen to bring them up. ...
Stem cells come up short in heart repair, study says Mar 1, 2006
Contra Costa Times, ...attack. The patients were randomly assigned to receive injections of a placebo or Neupogen, a bone marrow-stimulating drug. Tests ...
US Study Fails to Confirm Benefits of Autologous Stem Cell ... Mar 14, 2006
Cancer Consultants (press release), This study called for VAD (vincristine, Adriamycin and dexamethasone) induction and cyclophosphamide/Neupogen® mobilization of peripheral blood stem cells in ...
Dacogen™ Improves Outcomes in Myelodysplastic Syndromes Mar 15, 2006
Cancer Consultants (press release), ...were available to one where the supportive growth factors erythropoietin (EPO) and granulocyte colony stimulating factors (G-CSF, Neupogen®) are improving ...
March is National Nutrition Month: Introducing The Annie Appleseed ... Mar 3, 2006
PR Web (press release), ...can also lead to more serious conditions, like an increased risk of blood clots and the need for very expensive “rescue drugs,� such as Procrit and Neupogen ...
No Long-Term Adverse Effects of Neupogen® Given After Allogeneic ... Dec 13, 2005
Cancer Consultants (press release), Researchers affiliated with the International Bone Marrow Transplant Registry (IBMTR) have reported that the administration of Neupogen (filgrastim) following ...
Drug duo: New hope in cancer fight Dec 18, 2005
Macon Telegraph, ...again. Doctors have routinely given transplant patients a drug called Neupogen to coax the bone marrow to produce more stem cells. ...
Tandem High-Dose Chemotherapy Superior to Dose-Dense Chemotherapy ... Dec 5, 2005
Cancer Consultants (press release), ...because the infusion of stem cells assures rapid recovery of both neutrophils and platelets while current growth factor therapy with Neupogen® (filgrastim) or ...
Long-Term Safety of Dose-Dense Adjuvant Chemotherapy for Breast ... Dec 8, 2005
Cancer Consultants (press release), GONO-MIG) has reported that a dose-dense regimen of fluorouracil, epirubicin, and cyclophosphamide (FEC) given every 2 weeks with Neupogen® (filgrastim) was ...
Abraxane™ Safe When Used in Dose-Dense Therapy Regimen for ... Dec 19, 2005
Cancer Consultants (press release), Twenty-seven out of 29 patients were able to receive Abraxane, with one-third of these patients receiving Neupogen® (filgrastim). ...
Zacks.com announces that Richard Moroney highlights the following ... Dec 15, 2005
Business Wire (press release), They manufacture and market four human therapeutic products, EPOGEN(R) (Epoetin alfa), NEUPOGEN(R) (Filgrastim), INFERGEN(R) (Interferon alfacon-1) and STEMGEN ...
Amgen "outperform" Dec 1, 2005
New Ratings ...of Amgen’s Aranesp would be boosted by an increasingly binary market, given the company’s competitive leverage from offering Aranesp, Neupogen and Neulasta ...
Neulasta® and Aranesp® Provide Effective Hematopoietic Support ... Nov 21, 2005
Cancer Consultants (press release), Recombinant granulocyte-colony stimulating factors (Neupogen® and Neulasta) are also routinely used to prevent febrile neutropenia. ...
High-dose Chemotherapy Plus Growth Factor Helps in Locally ... Dec 2, 2005
MedPage Today, ...trial, women with at least 10 positive axillary lymph nodes who were randomly assigned to accelerated high-dose chemotherapy plus Neupogen (filgrastim) support ...
Former pharmacy owner sent to prison Dec 10, 2005
The Journal News.com, Procrit and Epogen. They also included Neupogen, which prevents infections in patients undergoing certain cancer treatments. Thom O ...
Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... Dec 7, 2005
Cancer Consultants (press release), ...were available to one in which the supportive growth factors erythropoietin (EPO) and granulocyte colony stimulating factors (G-CSF, Neupogen®) are improving ...
Abelson-Taylor Promotes Four to Account Director Dec 5, 2005
PharmaLive.com (press release), ...executive in 1997, she has handled product launches and rebranding for several brands in oncology and neurology, including Amgen's Neupogen (filgrastim), a ...
Biotech Earnings Jump In Quarter Nov 21, 2005
Chemical & Engineering News ...$668 million. And combined sales of the infection fighters Neulasta and Neupogen enjoyed a 17% jump to $882 million. In contrast ...
|
|
